RedHill Biopharma announced a new U.S. patent for its drug Talicia, which treats H. pylori infection, extending protection until February 12, 2034. This patent reinforces Talicia's status as the only FDA-approved, all-in-one therapy for H. pylori, a condition affecting about 35% of U.S. adults.